Why Worthington Steel Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket

Benzinga · 9h ago
Shares of Worthington Steel, Inc. (NYSE:WS) rose sharply in today's pre-market trading as the company reported stronger-than-expected financial results for the fourth quarter.
The company reported quarterly earnings of $1.05 per share, which beat the analyst consensus estimate of 82 cents per share.
Worthington Steel shares jumped 15.7% to $30.38 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
Gainers
- Vor Biopharma Inc. (NASDAQ:VOR) surged 105.6% to $1.14 in pre-market trading. Vor Bio and RemeGen signed a global license agreement for autoimmune asset Telitacicept, securing $125 million payment and $175 million private placement.
- Adial Pharmaceuticals, Inc (NASDAQ:ADIL) gained 51.2% to $0.3719 in pre-market trading. Adial Pharmaceuticals shares gained 7% on Wednesday after the company announced it secured AD04 production agreements with Cambrex and Thermo Fisher Scientific ahead of its New Drug Application submission to the FDA for the treatment of Alcohol Use Disorder.
- MKDWELL Tech Inc. (NASDAQ:MKDW) gained 30% to $0.3061 in pre-market trading.
- Baird Medical Investment Holdings Limited (NASDAQ:BDMD) rose 17.5% to $7.80 in pre-market trading after gaining 4% on Wednesday.
- KWESST Micro Systems Inc. (NASDAQ:KWE) jumped 17.4% to $8.50 in pre-market trading after falling 17% on Wednesday.
- Beeline Holdings, Inc. (NASDAQ:BLNE) climbed 16.6% to $1.54 in pre-market trading after falling 7% on Wednesday.
- Nano Labs Ltd (NASDAQ:NA) gained 14.2% to $12.95 in pre-market trading after dipping 24% on Wednesday.
- Altimmune, Inc. (NASDAQ:ALT) rose 12.8% to $8.70 in pre-market trading. Altimmune will announce 24-week data from IMPACT Phase 2b trial of Pemvidutide in MASH treatment on June 26.
- MillerKnoll, Inc. (NASDAQ:MLKN) gained 10.7% to $19.50 in pre-market trading after the company reported better-than-expected quarterly EPS and sales.
Losers
- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) shares tumbled 30.2% to $0.5310 in pre-market trading after the company announced a proposed public offering.
- Globavend Holdings Limited (NASDAQ:GVH) dipped 12.2% to $0.6105 in pre-market trading after dipping 44% on Wednesday.
- ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) fell 10.7% to $0.6335 in pre-market trading. ZyVersa Therapeutics, on Wednesday, announced a share purchase agreement for up to $10 million in partnership with Williamsburg Venture Holdings to fund clinical development of Cholesterol Efflux Mediator™ VAR 200.
- GlucoTrack, Inc. (NASDAQ:GCTK) dipped 9.4% to $7.10 in pre-market trading. Glucotrack shares jumped 26% on Wednesday after the company and OneTwo Analytics presented final results of their first-in-human study for a continuous blood glucose monitor, which met all primary and secondary endpoints.
- Wag! Group Co. (NASDAQ:PET) declined 9% to $0.0975 in pre-market trading after gaining 6% on Wednesday.
- XCF Global, Inc. (NASDAQ:SAFX) fell 8.8% to $2.07 in pre-market trading after surging more than 32% on Wednesday.
- Portage Biotech Inc. (NASDAQ:PRTG) declined 7.5% to $5.65 in pre-market trading. Portage Biotech shares gained 7% on Wednesday after the company announced it regained Nasdaq compliance.
- Kratos Defense & Security Solutions, Inc. (NASDAQ:KTOS) fell 7% to $39.38 in pre-market trading after the company priced its public offering of common stock.
- Crescent Biopharma, Inc (NASDAQ:CBIO) shares fell 6.2% to $16.89 in pre-market trading. Stifel, on Wednesday, initiated coverage on the stock with a Buy rating and announced a price target of $28.
- Oriental Rise Holdings Limited (NASDAQ:ORIS) fell 5% to $0.5992 in pre-market trading after dipping around 32% on Wednesday.
Now Read This:
Photo via Shutterstock
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.